A new review [1] of anti-androgens mentions Ralaniten (aka EPI-506) as a:
"novel first-in-class drug ... which binds to a unique region in the N-terminus domain of both the full-length and the truncated constitutively active splice variants of the AR, {&} is currently in clinical trials for patients who previously received abiraterone, enzalutamide, or both."
i.e. could be useful with Zytiga/Xtandi resistance due to AR-V7.
(The only additional thing I can discover about it from PubMed is that it is derived from a sponge [2].)
Unfortunately, the clinical trial "Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer" has been terminated:
"At end of Phase 1 excessive high pill burden (18 capsules/day)" [3]
18 caps? Why, that's nothing to Nalakrats. I've seen him take handfuls before, during & after lunch!
-Patrick
[1] ncbi.nlm.nih.gov/pubmed/294...